Spatial meta-transcriptomics reveal associations of intratumor bacteria burden with lung cancer cells showing a distinct oncogenic signature.
lung neoplasms
translational medical research
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
accepted:
31
05
2022
entrez:
6
7
2022
pubmed:
7
7
2022
medline:
9
7
2022
Statut:
ppublish
Résumé
The lung intratumor microbiome influences lung cancer tumorigenesis and treatment responses, but detailed data on the extent, location, and effects of microbes within lung tumors are missing, information needed for improved prognosis and treatment. To address this gap, we developed a novel spatial meta-transcriptomic method simultaneously detecting the expression level of 1,811 host genes and 3 microbe targets (bacteria, fungi, and cytomegalovirus). After rigorous validation, we analyzed the spatial meta-transcriptomic profiles of tumor cells, T cells, macrophages, other immune cells, and stroma in surgically resected tumor samples from 12 patients with early-stage lung cancer. Bacterial burden was significantly higher in tumor cells compared with T cells, macrophages, other immune cells, and stroma. This burden increased from tumor-adjacent normal lung and tertiary lymphoid structures to tumor cells to the airways, suggesting that lung intratumor bacteria derive from the latter route of entry. Expression of oncogenic β-catenin was strongly correlated with bacterial burden, as were tumor histological subtypes and environmental factors. Intratumor bacteria were enriched with tumor cells and associated with multiple oncogenic pathways, supporting a rationale for reducing the local intratumor microbiome in lung cancer for patient benefit. NCT00242723, NCT02146170.
Sections du résumé
BACKGROUND
The lung intratumor microbiome influences lung cancer tumorigenesis and treatment responses, but detailed data on the extent, location, and effects of microbes within lung tumors are missing, information needed for improved prognosis and treatment.
METHODS
To address this gap, we developed a novel spatial meta-transcriptomic method simultaneously detecting the expression level of 1,811 host genes and 3 microbe targets (bacteria, fungi, and cytomegalovirus). After rigorous validation, we analyzed the spatial meta-transcriptomic profiles of tumor cells, T cells, macrophages, other immune cells, and stroma in surgically resected tumor samples from 12 patients with early-stage lung cancer.
RESULTS
Bacterial burden was significantly higher in tumor cells compared with T cells, macrophages, other immune cells, and stroma. This burden increased from tumor-adjacent normal lung and tertiary lymphoid structures to tumor cells to the airways, suggesting that lung intratumor bacteria derive from the latter route of entry. Expression of oncogenic β-catenin was strongly correlated with bacterial burden, as were tumor histological subtypes and environmental factors.
CONCLUSIONS
Intratumor bacteria were enriched with tumor cells and associated with multiple oncogenic pathways, supporting a rationale for reducing the local intratumor microbiome in lung cancer for patient benefit.
TRIAL REGISTRATION NUMBER
NCT00242723, NCT02146170.
Identifiants
pubmed: 35793869
pii: jitc-2022-004698
doi: 10.1136/jitc-2022-004698
pmc: PMC9260850
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02146170', 'NCT00242723']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: PD is an employee and stockholder at NanoString Technologies. All other authors declare no competing interests. YZ is currently an employee at GlaxoSmithKline. All other authors declare no competing interests.
Références
Cell Host Microbe. 2013 Aug 14;14(2):195-206
pubmed: 23954158
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Protein Cell. 2021 May;12(5):426-435
pubmed: 33296049
Nat Rev Microbiol. 2017 May;15(5):259-270
pubmed: 28316330
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Lancet. 2021 Aug 7;398(10299):535-554
pubmed: 34273294
Nat Biotechnol. 2020 May;38(5):586-599
pubmed: 32393914
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
Cell. 2019 Feb 21;176(5):998-1013.e16
pubmed: 30712876
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Ann Transl Med. 2019 Aug;7(15):357
pubmed: 31516903
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Nature. 2021 Jul;595(7865):107-113
pubmed: 33915569
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
NPJ Precis Oncol. 2020 Dec 10;4(1):33
pubmed: 33303906
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Cancer Cell. 2021 Oct 11;39(10):1317-1341
pubmed: 34506740
Sci Rep. 2020 Dec 9;10(1):21530
pubmed: 33299035
Nature. 2021 Apr;592(7852):138-143
pubmed: 33731925
Oncoimmunology. 2015 Jun 3;4(8):e1021542
pubmed: 26405577
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Front Immunol. 2021 May 24;12:679829
pubmed: 34108973
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Nat Rev Immunol. 2009 May;9(5):377-84
pubmed: 19330016